Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL

This study aims to evaluate the efficacy and safety of the VPX regimen, a novel combination of teniposide, PD-1 monoclonal antibody and selinexor, in patients with relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL) who have progressed after high-dose methotrexate (HD-MTX)-based systemic therapy. By investigating this therapeutic approach, we seek to establish a new treatment paradigm that may improve clinical outcomes of this high-risk population.

Trial Details

NCT ID
NCT07074470
Phase
NA
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
  • Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning
  • Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor)
  • Consolidation therapy-whole brain radiation therapy
  • Maintenance treatment-PD-1 monoclonal antibody
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Age between 18 and 75 years old (inclusive).
  • Participants must be able to understand and willing to sign a written informed consent form.
  • The Eastern Cooperative Oncology Group is in a state of 0 to 3.
  • The expected lifespan is ≥ 3 months (according to researchers).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →